Personalized, Transdiagnostic Approach to Preventative Mental Health
A Personalized, Transdiagnostic Approach to Preventative Mental Health Using Machine Learning
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Michael K Owens
- Phone Number: 251-454-6659
- Email: mko@introspect.co
Study Locations
-
-
California
-
San Francisco, California, United States, 94103
- Recruiting
- California Institute of Integral Studies
-
Contact:
- Kris Brandenburger, Phd
- Phone Number: 415-575-3411
- Email: kbrandenburger@ciis.edu
-
Contact:
- Anne Huffman, Phd
- Email: ahuffman@ciis.edu
-
Principal Investigator:
- Michael K Owens
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- English fluency
- US citizen
- California resident
- Eligible to receive mental healthcare in the state of California
- Primary user of a smartphone device
- Daily access to Internet and email
- Meets a minimum level of 2.51 or higher on a self-rated technology use scale based on the average score of three Likert-style questions
- Willing to answer questions about themselves pertaining to physical and mental wellness throughout the Research Period
Exclusion Criteria:
- Undergoing care for condition requiring emergent treatment or hospitalization, including but not limited to: current or recent (within 3 months) acute manic or major depressive episode, clear and current suicidal risk, current or recent (within 3 months) history of substance abuse or drug dependence
- Undergoing active treatment for a condition wherein the additional burden of performing daily assessments may interfere with their pre-existing treatment regiment, cause undue anxiety, or risk inflammation of pre-existing issues
- Undergoing active treatment using a treatment modality that may adversely interact with research study participation such as psychopharmaceuticals affecting memory and cognition, therapeutic digital detox, or similar treatments
- Has ever participated in a Research Study testing the efficacy of transdiagnostic assessments, transdiagnostic interventions, or Internet-based CBT
- Additionally, patients on psychotropic medications are only eligible to be included while they maintain a stable dosage of their medication; if their medication dosage needs to change for any reason during the course of the Research Study, they would be required to withdraw from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Personalized, Transdiagnostic Assessments
One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm.
The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics.
Questions are scored immediately upon submission, regardless of how many questions are answered.
As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
|
Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools.
The software is delivered via the internet using a mobile device or computer.
|
|
Active Comparator: Monotopic Assessments
Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake.
The assessments will be scored in totality or not at all and have a fixed, predefined number of questions.
No personalization of assessment will take place.
|
Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools.
The software is delivered via the internet using a mobile device or computer.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Report Adherence Rate
Time Frame: 6 weeks
|
Frequency of individuals adhering to the regiment of daily self-assessments, segmented by arm
|
6 weeks
|
|
Completed Assessments Scored
Time Frame: 6 weeks
|
Total number of self-assessments completed throughout the study time frame, not including partial assessments, segmented by arm
|
6 weeks
|
|
Assessment Questions Scored
Time Frame: 6 weeks
|
Total number of individual questions completed throughout the study time frame, segmented by arm
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time per Assessment Question
Time Frame: 6 weeks
|
Average time spent responding to each question during an assessment, segmented by arm and assessment
|
6 weeks
|
|
Response Time
Time Frame: 6 weeks
|
Average time from initial assessment prompt to completion of the assessment, segmented by arm and assessment
|
6 weeks
|
|
Assessment Completion Rate
Time Frame: 6 weeks
|
Frequency of individuals completing an assessment, segmented by arm and assessment
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Anne M Huffman, PhD, California Institute of Integral Studies
- Principal Investigator: Michael K Owens, Introspect Health
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IH-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.